secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269479
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports patient death in nex-z trial; awaits FDA clinical hold; lonvo-z on track
--------------------------------------------------------------------------------

- Patient who had Grade 4 liver transaminase elevations after nex-z dose in MAGNITUDE Phase 3 trial died; FDA clinical hold letter pending.
- Phase 3 HAELO trial of lonvo-z for hereditary angioedema completed enrollment; topline data expected mid-2026.
- Cash, equivalents and marketable securities ~$670M as of Sept 30, 2025; company expects to fund ops into mid-2027.
- Longer-term Phase 1 clinical data for nex-z in ATTR-CM to be presented Nov 10 at AHA 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525269479/0001193125-25-269479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525269479/d53244d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer